Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Protagonist Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Neurogene Inc. June 12, 202594.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 6, 2025 | Metagenomi Therapeutics Inc. | Open-market sale | −5,239 | $1.75 | $9,168 |
| Apr 1, 2025 | Metagenomi Therapeutics Inc. | Grant or award | +14,000 | — | — |
| Apr 1, 2024 | Metagenomi Therapeutics Inc. | Grant or award | +57,763 | — | — |
Questions about Sarah B. Noonberg
What boards is Sarah B. Noonberg on?
Sarah B. Noonberg sits on the boards of Neurogene Inc. and Protagonist Therapeutics Inc.
How long has Sarah B. Noonberg served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.